Transgenic Monkey Model Of The Polyglutamine Diseases Recapitulating Progressive Neurological Symptoms And Polyglutamine Protein Inclusions

Background: To elucidate the pathomechanisms of and to develop potential therapies for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and the polyglutamine (polyQ) diseases, various rodent models have been developed so far. However, they have limitations in the translational research owing to the differences in the brain structure and functions, and drug metabolism between humans and rodents. Therefore, clinically-relevant non-human primate models of neurodegenerative diseases have been eagerly anticipated.